Gene therapies are the Holy Grail of medicine: they could cure over 6000 diseases, affecting 1Bn people, and worth over $1.2Tn.
However, 90% of gene therapies developed today fail clinical trials and are not approved. This is because the human immune system sees them as dangerous, initiating immune reactions that harm the patient and destroy the therapy.
At Crane Biosciences, we are building a platform to hide therapies from the immune system, preventing immune reactions and creating successful treatments.
We call this process “immuno-cloaking.”
Deep-tech Engineer with business background, 2x founder, >$1.5Mn raised
PhD in Molecular Biology from the Francis Crick Institute, Marie Curie Fellow
PhD in Chemistry from Vanderbilt University with focus on computational peptide design
